MDXG News and Press, MiMedx Group Inc From 12/07/21

Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy Demonstrates Sustainable Double-digit Growth Potential in Multiple Underpenetrate...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET MARIETTA, Ga., Nov. 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for...

MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Office...

MIMEDX PURION® Processed Placental Allografts Proved Safer Than Autologous Tissue, Reducing Infection, Scarring and Reoperation Rates MARIETTA, Ga., Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an...

MiMedx Group, Inc. (MDXG) Q3 2021 Earnings Conference Call November 3, 2021 08:30 ET Company Participants Alexandra Haden - General Counsel & Secretary Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive Vice President & Chief Commerci...

Shares of wound care company MiMedx Group (MDXG +14.5%) are up in trading today after reporting Q3 2021 EPS and revenue that beat Street expectations. MiMedx's net loss in the quarter narrowed ~88% to ~2.3M. R&D expenses increased 29% to $4.4M due to an increase in headcount in clinical r...

MiMedx Group (NASDAQ:MDXG): Q3 GAAP EPS of -$0.04 beats by $0.05. Revenue of $63.07M (-1.9% Y/Y) beats by $2.81M. Press Release For further details see: MiMedx Group EPS beats by $0.05, beats on revenue

Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20 Adjusted Net Sales of $62.8 Million Include a 13% Increase in Core Portfolio Sales Versus 3Q20 Year-to-Date Adjusted Net Sales Increase of 16% in Core Portfolio Sales Versus Prior Year Period Refl...

ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...